John Oyler Sells 1,949 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 1,949 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $257.24, for a total transaction of $501,360.76. Following the completion of the transaction, the chief executive officer owned 5,697,649 shares of the company’s stock, valued at $1,465,663,228.76. This trade represents a 0.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Oyler also recently made the following trade(s):

• On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The stock was sold at an average price of $270.56, for a total transaction of $1,336,566.40.

BeOne Medicines Stock Down 1.6%

Shares of BeOne Medicines stock opened at $263.92 on Wednesday. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. The company has a 50-day moving average of $297.63 and a 200 day moving average of $313.49. The firm has a market cap of $28.96 billion, a price-to-earnings ratio of 59.04 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $239.25 and a 1 year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. The company had revenue of $1.51 billion during the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. As a group, sell-side analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ONC has been the subject of several research reports. Leerink Partners increased their price target on shares of BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a research note on Friday, May 15th. Barclays increased their price target on shares of BeOne Medicines from $405.00 to $409.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a research note on Monday, April 20th. Morgan Stanley reiterated an “overweight” rating and issued a $395.00 price target on shares of BeOne Medicines in a research note on Thursday, May 7th. Finally, Wolfe Research initiated coverage on shares of BeOne Medicines in a research note on Friday, March 27th. They issued an “outperform” rating and a $340.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $390.00.

Institutional Trading of BeOne Medicines

Institutional investors and hedge funds have recently bought and sold shares of the company. Fiera Capital Corp increased its stake in BeOne Medicines by 20.1% during the 3rd quarter. Fiera Capital Corp now owns 25,117 shares of the company’s stock valued at $8,557,000 after purchasing an additional 4,205 shares in the last quarter. BNP Paribas Financial Markets increased its stake in BeOne Medicines by 100.6% during the 4th quarter. BNP Paribas Financial Markets now owns 193,951 shares of the company’s stock valued at $58,924,000 after purchasing an additional 97,244 shares in the last quarter. Slow Capital Inc. increased its stake in BeOne Medicines by 51.5% during the 4th quarter. Slow Capital Inc. now owns 27,301 shares of the company’s stock valued at $8,294,000 after purchasing an additional 9,280 shares in the last quarter. Generali Investments Management Co LLC bought a new stake in BeOne Medicines during the 3rd quarter valued at about $2,726,000. Finally, Capital International Sarl increased its stake in BeOne Medicines by 2.7% during the 4th quarter. Capital International Sarl now owns 152,515 shares of the company’s stock valued at $46,336,000 after purchasing an additional 3,956 shares in the last quarter. 48.55% of the stock is currently owned by institutional investors.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.